Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Jane Street Group LLC

Jane Street Group LLC trimmed its stake in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 71.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 42,272 shares of the company’s stock after selling 103,504 shares during the quarter. Jane Street Group LLC’s holdings in Ventyx Biosciences were worth $92,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in the stock. Palumbo Wealth Management LLC bought a new stake in Ventyx Biosciences in the third quarter valued at $26,000. China Universal Asset Management Co. Ltd. grew its position in Ventyx Biosciences by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock worth $30,000 after purchasing an additional 5,310 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Ventyx Biosciences in the third quarter valued at approximately $42,000. The Manufacturers Life Insurance Company raised its holdings in shares of Ventyx Biosciences by 41.1% during the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after buying an additional 7,096 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Ventyx Biosciences during the second quarter valued at approximately $58,000. Institutional investors own 97.88% of the company’s stock.

Analyst Ratings Changes

VTYX has been the topic of several recent analyst reports. Oppenheimer reaffirmed an “outperform” rating and set a $9.00 target price (down previously from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. HC Wainwright reissued a “neutral” rating on shares of Ventyx Biosciences in a report on Tuesday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $10.00.

Insider Transactions at Ventyx Biosciences

In other news, insider John Nuss sold 13,161 shares of the business’s stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $2.26, for a total transaction of $29,743.86. Following the sale, the insider now directly owns 485,701 shares in the company, valued at approximately $1,097,684.26. The trade was a 2.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Raju Mohan bought 261,752 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was acquired at an average cost of $2.01 per share, for a total transaction of $526,121.52. Following the purchase, the chief executive officer now owns 2,175,028 shares of the company’s stock, valued at $4,371,806.28. This trade represents a 13.68 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders bought 630,000 shares of company stock worth $1,262,415. 18.18% of the stock is owned by insiders.

Ventyx Biosciences Price Performance

Shares of VTYX stock opened at $1.94 on Wednesday. Ventyx Biosciences, Inc. has a fifty-two week low of $1.67 and a fifty-two week high of $11.48. The stock’s 50-day moving average is $2.29 and its two-hundred day moving average is $2.28. The firm has a market cap of $137.18 million, a P/E ratio of -0.82 and a beta of 0.55.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.